ARTICLE | Company News
FDA approves Rituxan for pemphigus vulgaris
June 7, 2018 11:31 PM UTC
FDA approved Genentech Inc.’s Rituxan rituximab to treat moderate to severe pemphigus vulgaris. The Roche (SIX:ROG; OTCQX:RHHBY) unit said Rituxan is the first biologic approved by the agency for the disease and the first FDA-approved treatment for the indication in more than 60 years.
The chimeric mAb against CD20 antigen has breakthrough therapy and Orphan Drug status from FDA for the indication. ...